Hansa Biopharma presented new data on imlifidase at the European Society for Organ Transplantation (ESOT) Congress
· Hansa presented two abstracts on imlifidase, adding to the body of evidence that supports the use of imlifidase in enabling transplantation in highly sensitized patients · Hansa also hosted a symposium at ESOT with five experts on enabling transplantation for highly sensitized patients Lund, Sweden September 1, 2021. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announced two abstracts presented at the European Society for Organ Transplantation (ESOT) Congress, August 29-September 1, 2021. The